Piper Sandler Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)
Piper Sandler's Edward Tenthoff reiterated a Buy rating for Kymera Therapeutics with a $98 price target. Tenthoff, who covers the Healthcare sector, has an average return of -8.8% and a 33.95% success rate. Morgan Stanley also maintained a Buy rating with a $73 price target. The report highlights investment insights and research tools offered by TipRanks.
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Kymera Therapeutics, with a price target of $98.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
According to TipRanks, Tenthoff is an analyst with an average return of -8.8% and a 33.95% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals.
In a report released on December 1, Morgan Stanley also maintained a Buy rating on the stock with a $73.00 price target.
